Company Insights

DRIO customer relationships

Explore interactive graphBrowse insights index
DRIO customer relationship map

DarioHealth (DRIO) — Customer Relationships Signal a B2B2C Scaling Play with Concentration Risk

DarioHealth sells a digital health engagement platform and adjacent hardware to employers, health plans and consumers, monetizing primarily through subscription contracts priced per member/per engaged member and supplemented by hardware sales and fee-for-service clinical care. The company’s commercial traction with health plans, large employers and channel partners drives revenue growth but also concentrates economic exposure; investors should weigh rapid B2B2C distribution against a material client concentration signal and mixed margin dynamics.

For a succinct, relationship-focused view of Dario’s commercial footprint, see NullExposure’s research hub: https://nullexposure.com/

Why the customer list matters for valuation and operational risk

Dario’s GTM is built around three levers: recurring subscription revenue, add-on clinical services billed variably, and hardware sales. That mix creates predictable recurring cash flows when adoption scales but produces lumpy revenue from hardware and FFS clinical add-ons. The company reports that its B2B segments now represent roughly three-quarters of revenues, and its major customer represented 41.6% of accounts receivable as of December 31, 2024 — a concentration that materially affects downside risk and contract negotiation leverage. The commercial model is largely seller-led: Dario sells platform access to large enterprises and plans and distributes through channel partners, accelerating scale but increasing dependency on a small number of large counterparties.

Explore client-level exposure and commercial intelligence at NullExposure: https://nullexposure.com/

Customer roll-call — every relationship documented in public filings and calls

  • Primera Blue Cross — Dario was launched with Primera as part of Solara Health’s channel in the Pacific Northwest; the company cited this launch on its 2025 Q3 earnings call (2025 Q3 / transcript noted March 2026).
    Source: Dario 2025 Q3 earnings call transcript (first reported March 7, 2026).

  • Florida Blue — Dario is part of a new Amwell-selected arrangement with Florida Blue, where Dario provides diabetes and cardiometabolic solutions across insured and self-insured lines as noted in the 2025 Q3 commentary.
    Source: Dario 2025 Q3 earnings remarks and related Amwell disclosure (2025 Q3; cited March 2026).

  • Blue Shield of California — Blue Shield expanded its Wellvolution platform to include Dario’s at‑home hypertension solution and Spanish-language accessibility as announced in a Blue Shield press release in November 2023.
    Source: Blue Shield of California press release (Nov 29, 2023) via news.blueshieldca.com.

  • UnitedHealthcare — UnitedHealthcare performed a soft launch of the full Dario suite on its digital marketplace in 2025 with a full national rollout scheduled for January 2026, according to Dario’s 2025 Q3 call and supporting news transcripts.
    Source: Dario 2025 Q3 earnings call and related transcript coverage (FY2025 / 2025 Q3; reported March 2026).

  • Aetna — A Solara Health arrangement referenced by Dario indicated that Solara and its partner Aetna selected Dario to serve a large employer population totaling 126,000 lives, as described on the company’s Q3 2025 call and transcript.
    Source: Dario 2025 Q3 earnings call and transcript coverage (2025 Q3 / FY2025; March 2026).

  • Eli Lilly — Dario (and its Twill product) has been engaged with major pharmaceutical partners including Eli Lilly, as referenced in the company’s public remarks about pharma customer breadth.
    Source: Dario commentary on partnerships cited in Q3 2025 earnings transcript (FY2025; March 2026).

  • Novo Nordisk — Novo Nordisk is listed among the pharmaceutical clients Dario or Twill has served, reflecting the company’s commercial relationships across major biopharma firms.
    Source: Dario Q3 2025 transcript commentary on pharma customers (FY2025; March 2026).

  • Sanofi — Sanofi is named alongside other major pharma clients of Dario/Twill, signaling established engagement with legacy and modern drugmakers.
    Source: Dario Q3 2025 transcript commentary (FY2025; March 2026).

  • Solara Health — Solara is described as a powerful digital channel partner where Dario is a preferred partner; Solara enables distribution to large health plans and employer groups.
    Source: Dario Q3 2025 earnings call and transcript (FY2025; March 2026).

  • Amwell — Amwell selected by Florida Blue disclosed that Dario was chosen as part of the new business, positioning Amwell as a meaningful channel for Dario’s plan-level distribution.
    Source: Amwell-related disclosures referenced in Dario’s Q3 2025 call and public Amwell earnings commentary (FY2025; March 2026).

What these relationships reveal about the operating model and commercial constraints

  • Contracting posture: Dario’s revenue is primarily subscription-based, priced PMPM/PEMPM, which creates recurring revenue but ties retention to sustained engagement; clinical services can be usage‑based (FFS) for higher-margin care. This subscription-first posture aligns incentives with engagement metrics rather than one-off device sales.
    Source: Company filings and revenue recognition disclosures across 2024–2025.

  • Counterparty mix and concentration: The company sells to individuals, large enterprises, and very large enterprises through direct and channel routes; this mix accelerates growth but creates material concentration — one major customer represented 41.6% of accounts receivable at year-end 2024. That concentration is a critical valuation and negotiation risk.
    Source: 2024 financial disclosures and customer segmentation commentary.

  • Criticality and maturity: Relationships with national payers (UnitedHealthcare, Aetna, Blue Shield, Florida Blue) and channel partners (Solara, Amwell) indicate enterprise-grade deployments, with some pilots and soft launches transitioning to national rollouts (UnitedHealthcare). Dario reports active contracts (53 employers in 2024) alongside pilots and ramping deals, indicating a mixed maturity curve.
    Source: 2024–2025 company statements and Q3 2025 earnings call.

  • Product segmentation: Revenue streams split across services (coaching, software), hardware (monitors), and regulated software (medical device approvals), which produces both recurring and transactional revenue lines and requires ongoing clinical and regulatory investment.
    Source: Public filings describing revenue breakdown and product approvals.

Investment implications — how to think about upside and downside

  • Upside: Enterprise and channel distribution through large payers and partners can scale recurring SaaS revenue quickly and increase lifetime value per customer if engagement metrics hold. Deployments with UnitedHealthcare and major Blues plans are high-leverage commercial wins for valuation.
  • Downside: High customer concentration and hardware/service revenue variability create earnings volatility; biopharma and channel relationships expand reach but do not substitute for durable diversified plan and employer revenue. Retention and measurable clinical outcomes will be the ultimate value driver and the primary gating item for higher multiples.

Act on this customer intelligence and monitor rollouts and retention metrics at NullExposure: https://nullexposure.com/

Next steps for investors and operators

Track three signals closely: (1) national rollout progress (notably UnitedHealthcare’s January 2026 expansion), (2) revenue mix trends between subscription services and hardware/FFS, and (3) accounts receivable concentration trends to see whether the 41.6% major-customer exposure declines. These will determine whether Dario’s commercial momentum translates into durable margin expansion and de‑risked earnings.

For more granular customer exposure analysis and ongoing monitoring, visit NullExposure’s research center: https://nullexposure.com/